Here is what the page “Breakthrough Inhalable Nanoparticle Treatment Could Simplify Tuberculosis Care | Nova Glob” contains. Researchers at the University at Buffalo’s Jacobs School of Medicine have achieved a significant milestone in tuberculosis (TB) research, developing an inh... Researchers at the University at Buffalo’s Jacobs School of Medicine have achieved a significant milestone in tuberculosis (TB) research, developing an inhalable nanoparticle treatment that could transform patient care. By utilizing a beta-glucan and chitosan-PLGA carrier, scientists successfully delivered rifampin directly to the lungs in mouse models.
The findings, published in 'Antimicrobial Agents and Chemotherapy,' demonstrate that once-weekly doses of this inhaled therapy are as effective as the current standard of daily oral medication. This breakthrough addresses one of the primary obstacles in TB eradication: patient adherence. The demanding nature of daily, long-term oral therapy often leads to incomplete treatment and the subsequent development of drug-resistant strains. The full version stays on the original page, which this listing opens directly.